top of page

CC and its protocolized workflow provides for meaningful pain relief and opiate reduction

CareConvoy and its protocolized workflow provides for meaningful pain relief and opiate reduction

Duke Neurosurgery

Sarah E Hodges, BA; Shervin Rahimpour, MD; Luis A Antezana, BS; Abena A Ansah-Yeboah, BS; Rajeev Dharmapurikar, MS; John Hatehway, MD; Michael Warrick, MD; Scott Berlin, MD; Benjamin Seeman, DO; Shivanand P Lad, MD, PhD

Key Results

79%

Patients Experience 50%+ Pain Relief

52%

Patients Reduced Use of ‘As Needed’ Medications

87%

Would Recommend the Same Procedure

Introduction

  • Various new waveforms for spinal cord stimulation (SCS) have emerged in recent years, but with limited data supporting their utility in a real-world clinical setting.

  • We report real-world results of a protocolized workflow algorithm that allows for high dose (HD) and low dose (LD) neurostimulation in patients with chronic pain undergoing SCS trial or permanent procedures

Objectives

  • ​To assess if a protocolized workflow algorithm that allows for high dose (HD) and low dose (LD) Spinal Cord Stimulation (SCS) has utility and efficacy in a real-world clinical setting.

  • To determine if a protocolized workflow algorithm that offers HD and LD SCS can provide meaningful pain relief.

  • To evaluate whether a protocolized workflow algorithm that offers HD and LD SCS may hold promise for facilitating an opiate reduction in patients with chronic pain.

Methods

  • Prospective data was collected using the CareConvoy mobile device platform in patients undergoing Medtronic SCS trial and permanent implant procedures.

  • E-consent was obtained through the HIPAA compliant, mobile software platform.

  • All data were de-identified, aggregated, and analyzed.

Results

  • In total, 104 patients (37 trial SCS and 67 permanent SCS) participated.

  • For SCS trial and permanent procedures, the protocolized workflow algorithm resulted in a 91% trial success rate with >50% pain relief.

  • At long-term follow-up (3 to 12 months), 86% of permanent SCS patients reported they were getting the same or more relief as during their SCS trial.

  • For permanent SCS patients, 79% reported >50% improvement in overall pain and 58% had >50% improvement in low back pain.

  • The protocolized workflow algorithm resulted in a 37% ‘remitter rate’, with these patients reporting themselves to be essentially pain-free (VAS 0-3).

  • Importantly, 52% of permanent implant patients stopped or reduced their ‘as needed’ pain medications by >50%.

  • Additionally, 87% would recommend the same procedure to a friend or family member, 87% found device charging ‘easy’ or ‘very easy’ and 66% reported charing a few times a week or weekly.

Conclusion

  • A protocolized workflow algorithm that allows for high dose (HD) and low dose (LD) Spinal Cord Stimulation (SCS) appears to have robust utility and efficacy in a real-world clinical setting.

  • A protocolized workflow algorithm that offers HD and LD SCS can provide meaningful pain relief.

  • A protocolized workflow algorithm that offers HD and LD SCS shows great promise for facilitating an opiate reduction in patients with chronic pain; an intriguing possibility, particularly in light of the current opioid epidemic, that merits further evaluation, with an RCT and extended long-term follow-up in progress.

bottom of page